$ASMB News

Guggenheim Reiterates Buy on Assembly Biosciences, Maintains $43 Price Target

Assembly Biosciences Prices $100M Offering Of 3,358,602 At $26.50 Per Share And Warrants To Purchase Up To 415,000 Shares At Offer Price Of $26.499 Per Pre-Funded Warrant

Assembly Biosciences Announces Plans To Expand Clinical Development Of ABI-6250 Into Primary Biliary Cholangitis And Primary Sclerosing Cholangitis

Assembly Biosciences, Inc. (ASMB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Assembly Biosciences Q1 EPS $(0.54) Beats $(0.71) Estimate, Sales $8.213M Miss $9.266M Estimate

HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target

Assembly Biosciences, Inc. (ASMB) Presents at ESCMID Global 2026 - Slideshow

Assembly Biosciences Presents Phase 1b Data For ABI-5366 And ABI-1179 At ESCMID Global

Guggenheim Maintains Buy on Assembly Biosciences, Raises Price Target to $43

HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target

Assembly Biosciences Files Prospectus For Securities Offerings Up To $400M

Assembly Biosciences Q4 EPS $1.30 Beats $(0.65) Estimate, Sales $42.469M Beat $7.423M Estimate

Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates

Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates

With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors

Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes

HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target

Gilead Sciences Exercises Option To License Assembly Bio's Herpes Simplex Virus Helicase-Primase Inhibitor Programs

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript